87 related articles for article (PubMed ID: 15177491)
1. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
Blay JY; Le Cesne A; Verweij J; Scurr M; Seynaeve C; Bonvalot S; Hogendoorn P; Jimeno J; Evrard V; van Glabbeke M; Judson I
Eur J Cancer; 2004 Jun; 40(9):1327-31. PubMed ID: 15177491
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Le Cesne A; Blay JY; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen OS
J Clin Oncol; 2005 Jan; 23(3):576-84. PubMed ID: 15659504
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ET-743: the French experience.
Brain EG
Anticancer Drugs; 2002 May; 13 Suppl 1():S11-4. PubMed ID: 12173489
[TBL] [Abstract][Full Text] [Related]
4. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Ryan DP; Puchalski T; Supko JG; Harmon D; Maki R; Garcia-Carbonero R; Kuhlman C; Winkelman J; Merriam P; Quigley T; Jimeno J; Manola J; Demetri GD
Oncologist; 2002; 7(6):531-8. PubMed ID: 12490740
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
6. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747
[TBL] [Abstract][Full Text] [Related]
7. ET-743: the US experience in sarcomas of soft tissues.
Demetri GD
Anticancer Drugs; 2002 May; 13 Suppl 1():S7-9. PubMed ID: 12173492
[TBL] [Abstract][Full Text] [Related]
8. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
Trent JC; Beach J; Burgess MA; Papadopolous N; Chen LL; Benjamin RS; Patel SR
Cancer; 2003 Dec; 98(12):2693-9. PubMed ID: 14669291
[TBL] [Abstract][Full Text] [Related]
9. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Delaloge S; Yovine A; Taamma A; Riofrio M; Brain E; Raymond E; Cottu P; Goldwasser F; Jimeno J; Misset JL; Marty M; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1248-55. PubMed ID: 11230465
[TBL] [Abstract][Full Text] [Related]
10. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
12. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Garcia-Carbonero R; Supko JG; Maki RG; Manola J; Ryan DP; Harmon D; Puchalski TA; Goss G; Seiden MV; Waxman A; Quigley MT; Lopez T; Sancho MA; Jimeno J; Guzman C; Demetri GD
J Clin Oncol; 2005 Aug; 23(24):5484-92. PubMed ID: 16110008
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Paz-Ares L; Rivera-Herreros F; Díaz-Rubio E; García M; Casado E; Cubedo R; Gravalos C; Alfaro V; Gómez J; Izquierdo MA; Tabernero J
Clin Colorectal Cancer; 2007 May; 6(7):522-8. PubMed ID: 17553201
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL
J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
18. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
Therasse P; Le Cesne A; Van Glabbeke M; Verweij J; Judson I;
Eur J Cancer; 2005 Jul; 41(10):1426-30. PubMed ID: 15919202
[TBL] [Abstract][Full Text] [Related]
19. [Trabectedin registry].
Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Laverdiere C; Kolb EA; Supko JG; Gorlick R; Meyers PA; Maki RG; Wexler L; Demetri GD; Healey JH; Huvos AG; Goorin AM; Bagatell R; Ruiz-Casado A; Guzman C; Jimeno J; Harmon D
Cancer; 2003 Aug; 98(4):832-40. PubMed ID: 12910529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]